Current disease status-Recurrent cancer - Page 2 of 19 Posts on Medivizor
Navigation Menu

Current disease status-Recurrent cancer Posts on Medivizor

Comparing the long-term effects of two intensity modulated radiation therapies in localized prostate cancer

Comparing the long-term effects of two intensity modulated radiation therapies in localized prostate cancer

Posted by on Jun 28, 2020 in Prostate cancer | 0 comments

In a nutshell The study compared the long-term effects of moderate hypofractionated intensity-modulated radiation therapy (H-IMRT) and conventionally fractionated IMRT (C-IMRT) on outcomes in patients with localized prostate cancer (PC). The authors found that H-IMRT was similarly effective compared to C-IMRT after 10 years of therapy in such...

Read More

Does olaparib increase survival in patients with metastatic castration-resistant prostate cancer?

Does olaparib increase survival in patients with metastatic castration-resistant prostate cancer?

Posted by on Jun 27, 2020 in Prostate cancer | 0 comments

In a nutshell This study assessed whether olaparib (Lynparza) affected progression-free survival (PFS; survival without cancer worsening) in patients with metastatic castration-resistant prostate cancer (mCRPC) and certain genetic mutations (abnormalities). The study found that olaparib improved PFS in these patients. Some...

Read More

Can pembrolizumab combined with chemotherapy slow the progression of extensive stage small-cell lung cancer?

Can pembrolizumab combined with chemotherapy slow the progression of extensive stage small-cell lung cancer?

Posted by on Jun 10, 2020 in Lung cancer | 0 comments

In a nutshell The study evaluated the addition of pembrolizumab (Keytruda) to etoposide (Etopophos) and platinum chemotherapy drugs for patients with untreated extensive-stage (ES) small-cell lung cancer (SCLC). The study found that pembrolizumab improved progression-free survival (PFS; survival without cancer getting worse) when added to...

Read More

Do biological drugs work better alone or in combination with other drugs for patients with advanced non-small cell lung cancer who previously received treatment?

Posted by on Apr 7, 2020 in Lung cancer | 0 comments

In a nutshell This study compared if anti-PD-1 biological drugs were more effective alone or when used with other drugs to treat patients with advanced non-small cell lung cancer who had previously received treatment. The results showed that the combination of anti-PD-1 and other drugs such as chemotherapy improved patients’ survival more than...

Read More

The role of androgen deprivation therapy plus radiotherapy in the treatment of prostate cancer after prostate surgery

Posted by on Jan 12, 2020 in Prostate cancer | 0 comments

In a nutshell This study compared the safety and effectiveness of short-term androgen deprivation therapy (ADT) combined with radiotherapy (RT) in patients who underwent radical prostatectomy (RP). The main finding was that the combination of ADT and RT reduced the risk of recurrence and disease progression in these patients. Some background RP is...

Read More

Searching for men relapsed prostate cancer to test a treatment combination

Posted by on Apr 22, 2019 in Prostate cancer | 0 comments

In a nutshell This trial is looking at blocking androgens (male sex hormones) with different medications in men with raised PSA (a blood marker of prostate cancer) levels after prostate surgery. The main outcome to be measured will be the length of time the patients survive without the cancer progressing. This study is being conducted in the United...

Read More